Pharmacodiagnostics are considered the pathway to what has been termed “personalized medicine,” the use of molecular analysis to achieve optimum medical outcomes in the management of a patient’s disease or predisposition to disease. As such, personalized medicine promises to bring about a new standard of healthcare, with the possiblity to increase profits, speed clinical trials, achieve better clinical results and satisfy patients. But how can companies earn revenue in this undertaking? What are the likely challenges for pharma companies and IVD companies? Will the current eocnomy impact this emerging market?
This report, Pharmacodiagnostics and Personalized Medicine (Markets, Challenges, Forecasts and Key Players) presents a realistic look at the promise and pitfalls of personalized medicine, with important data useful for business planning and marketing efforts, including:
- Current Market Size for U.S. Pharmacodiagnostics
- Forecasted Likely and ‘Best Case’ Revenue Projections to 2018.
- An Overview of the Concept, Past Successes and Failures.
- Potential Pitfalls for PM Strategies
- Forecasts for Pharmacodiagnostics in the U.S. Cancer Treatment Markets (by type.)
- Possible Cardiological and Psychiatric Treatment Markets
- 8 Strategic Conclusions And Implications For Entrants in this Market
- Profiles of Key Players in Pharmacodiagnostics
Personalized Medicine has given the diagnostics field a huge boost in terms of publicity/public attention, revenue potential, and investment interest. Still questions exist as to how extensive such testing will be and how soon we will see its growth in clinical applications. There are many hurdles to be overcome, but researchers are confident they can be. For a thorough understanding of the impact that personalized medicine could have on pharmaceutical and diagnostic companies, this report reviews these important factors:
including the key challenges new entrants need to overcome to establish a revenue stream, genome costs, the likely ‘Shotgun Effect’ on Pharmaceutical product lines, the challenge of overcoming privacy concerns in the wake of the GINA legislation, competing cultures between diagnostic and pharmaceutical companies, and other factors.
There are numerous companies participating in this market and the number is growing. As part of its unique analysis, the following companies are profiled:
- Abbott Diagnostics
- Affymetrix, Inc.
- Althea Technologies
- Curidium Medica, PLC.
- Gen Probe
- Genzyme Corporation
- Perlegen Sciences
- Provista Life Sciences
- Theranostics Health
- Ventana Medical Systems
Because of its size and influence, this report (necessarily, Kalorama believes), focuses on the U.S. market.